Lexaria Bioscience Corp
NASDAQ:LEXX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lexaria Bioscience Corp
NASDAQ:LEXX
|
CA |
|
K
|
Kiwoom No.11 Special Purpose Acquisition Co
KOSDAQ:489480
|
KR |
|
L
|
Legrand SA
XMUN:LRC
|
FR |
Intrinsic Value
The intrinsic value of Lexaria Bioscience Corp (LEXX) under the Base Case is 0.3 USD per share.
Compared with the current market price of 4.17 USD, the stock appears
Overvalued by 93% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Lexaria Bioscience Does
Lexaria Bioscience Corp. develops drug-delivery technology that helps certain active ingredients work better when taken by mouth. Its main platform, DehydraTECH, is designed to improve how compounds such as cannabinoids, nicotine, and some prescription drugs are absorbed and used by the body. The company is not a drug maker in the usual sense; it builds the technology layer that can be added to other companies’ ingredients and formulations.
- Headquarters
- Canada CA
- Employees
- 7
- IPO date
- Oct 28, 2009
Revenue & Expenses Breakdown
Lexaria Bioscience Corp
Earnings Waterfall
Lexaria Bioscience Corp
The intrinsic value for Lexaria Bioscience Corp (LEXX) under the Base Case is 0.3 USD.
Compared with the current market price of 4.17 USD, the stock appears Overvalued by 93% .
